← back to search

John M. Russell

University of Glasgow · US
Area of research
Pulmonary and Respiratory Medicine · Computational Mechanics
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Fluid Dynamics and Turbulent Flows, and Radiopharmaceutical Chemistry and Applications.
h-index
29
citations
9,805
works
115
NIH funding
primary concept
Medicine
email

Recent publications

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
International Journal of Cancer 2022cited by 74position: middledoi
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
JNCI Cancer Spectrum 2022cited by 25position: middledoi
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Annals of Oncology 2020cited by 5position: middledoi
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Annals of Oncology 2019cited by 397position: middledoi
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
The Lancet 2018cited by 1,251position: middledoi
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Annals of Oncology 2018cited by 250position: middledoi
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
European Urology Oncology 2018cited by 27position: middledoi
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
New England Journal of Medicine 2017cited by 1,757position: middledoi
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
The Lancet 2015cited by 1,957position: middledoi

Grants

REU Site: Intelligent Manufacturing for a Sustainable Energy Future
NSF2447711$509,8092025–2028PIRePORTER
Experimental Studies of Quark Interactions
NSF9224790$150,0001993–1996PIRePORTER
Physics Alliances -- A Program for School-College Collaboration - (Continuation)
NSF8955376$389,3181990–1995PIRePORTER
Experimental Studies of Quark Interactions
NSF9000295$141,8401990–1993PIRePORTER
NMR Spectroscopy for Chemistry, Biochemistry, and Biology Students
NSF9051141$85,0001990–1992PIRePORTER
Physics Alliances - A Program for School-College Collaboratives
NSF8751392$177,9251987–1990PIRePORTER
Experimental Studies of Quark Interactions (Physics)
NSF8617879$120,0001987–1990PIRePORTER
Establishment of an Analytical Instrumentation Laboratory For Geological Investigations
NSF8405842$244,8001984–1987PIRePORTER
Experimental Studies of Quark Interactions (Physics)
NSF8316991$155,0001984–1987PIRePORTER
Experimental Studies of Quark Interactions
NSF8023435$150,0001981–1984PIRePORTER
Environmental Science Laboratory Equipment
NSF7914401$12,7001979–1982PIRePORTER
Study of Baryonium States
NSF7813405$60,8641978–1981PIRePORTER
Minority Institutions Science Improvement: Individual Institutional Project
NSF7516474$230,0001975–1977PIRePORTER
Environmental Education For Science Teachers
NSF7510694$96,5701975–1977PIRePORTER

Frequent collaborators

No co-authors indexed yet.